Stockscreener 앱 받기
0.253
0.00%
0.00
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DayConsensus Beat Rate - vinanet.vn
Theriva Biologics(TOVX) Stock Options Chain | Quotes & News - Moomoo
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportRounding Bottom - vinanet.vn
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneQuality Factor - vinanet.vn
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportSentiment Divergence - vinanet.vn
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria
Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView
Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative
Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView
Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan
Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com
Theriva Biologics 2Q Loss/Shr 7c >TOVX - Moomoo
BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa
Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 - GlobeNewswire
Theriva Biologics Expands Stock Incentive and Governance Plans - TipRanks
Theriva Biologics (NYSE American: TOVX) holders back bigger stock plan, warrants - Stock Titan
Theriva Biologics, Inc. Revenue Breakdown – AMEX:TOVX - TradingView
TOVX|Theriva Biologics Inc|Price:0.222|Chg%:+0.012 - TradingKey
Theriva Biologics Inc (TOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Theriva Biologics Inc (TOVX) Cash Flow - TradingKey
TOVX|Theriva Biologics Inc|Price:0.214|Chg%:-0.009 - TradingKey
Theriva Biologics Inc (TOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Theriva Biologics Inc (TOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Theriva Biologics Inc (TOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theriva Biologics, Inc. Revenue Breakdown – BOATS:TOVX - TradingView
Theriva Biologics Inc (TOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TOVX|Theriva Biologics Inc|Price:0.223|Chg%:-0.001 - TradingKey
Theriva Biologics (TOVX) Proxy Filing Summary - Quartr
Theriva Biologics (TOVX) Slides 5% as Selling Pressure Mounts Near Key SupportPCR Extreme - vinanet.vn
Theriva Biologics (TOVX) Declines 5.6% as Stock Tests Key Support LevelsAI Trade Signals - dars.gov.et
symbol__ Stock Quote Price and Forecast - CNN
Theriva Biologics (TOVX) Secures Approval for VIRAGE2 Clinical T - GuruFocus
Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy - Moomoo
Theriva Biologics launches VIRAGE2 metastatic pancreatic trial - TipRanks
Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan
Theriva Biologics receives approval to start VIRAGE2 cancer trial By Investing.com - Investing.com Canada
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - The Manila Times
Theriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trial - Stock Titan
Theriva Biologics (TOVX) Holds Steady Near Support After Modest GainOrder Block - DonanımHaber
Form DEF 14A THERIVA BIOLOGICS For: 29 June By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) puts large share and warrant proposals to vote - Stock Titan
Enterprise value to EBIT forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to book forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Enterprise value to EBIT forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Enterprise value to EBITDA forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Enterprise value to revenue forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Price to sales forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to earnings forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to earnings forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Theriva Biologics Company Profile & Introduction - Moomoo
Theriva Biologics, Inc. Actuals & Estimates (AMEX:TOVX) - TradingView
TOVX Forecast — Price Target — Prediction for 2027 - TradingView
Theriva Biologics, Inc. Actuals & Estimates (FWB:SFY0) - TradingView
0.86%
0.31%
자본화:
|
볼륨(24시간):